Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-11 |
mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-09 |
mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-09 |
mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-09 |
mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.19 | 7e-09 |
mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-08 |
mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-08 |
mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-08 |
mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-08 |